Aurinia Pharmaceuticals
IPO
Changing the Trajectory of Autoimmune Diseases
- Employees
- 51–200
- Business Model
- B2B
- Website
- auriniapharma.com
About
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on treating autoimmune diseases with high unmet medical needs. Its lead commercial product, LUPKYNIS (voclosporin), is approved for lupus nephritis. The company is advancing a pipeline including aritinercept for additional autoimmune indications.